This page contains brief information about tazemetostat hydrobromide and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Tazemetostat hydrobromide is approved to treat:
- Epithelioid sarcoma that is locally advanced or has metastasized (spread to other parts of the body). It is used in adults and in children aged 16 years or older whose disease cannot be removed by surgery.
This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that tazemetostat hydrobromide provides a clinical benefit in these patients.
Tazemetostat hydrobromide is also being studied in the treatment of other types of cancer.
More About Tazemetostat Hydrobromide
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Tazemetostat Hydrobromide - Check for trials from NCI's list of cancer clinical trials now accepting patients.